×
About 3,243 results

ALLMedicine™ Ovarian Insufficiency Center

Research & Reviews  1,585 results

Human Mesenchymal Stem Cell Therapy and Other Novel Treatment Approaches for Premature ...
https://doi.org/10.1007/s43032-021-00528-z 10.1016/S0140-6736(10)60355-8 10.1016/j.maturitas.2011.12.023 10.1210/er.2014-1020 10.1530/REP-13-0181 10.1016/j.rbmo.2015.06.015 10.1016/j.fertnstert.2013.11.009 10.1038/nrendo.2013.205 10.1258/ce.2009.009046 10.1186/s13287-019-1315-9 10.1186/s13287-017-0721-0 10.1371/journal.pone.0106538 10.1177/1933719117699705 10.1007/s11626-019-00337-4 10.1007/s11427-017-9272-2 10.1186/s13287-016-0458-1 10.1177/1933719117699705 10.1073/pnas.1312830110 10.4103/jhrs.JHRS_116_17 10.1016/j.fertnstert.2018.04.025 10.1080/09513590.2018.1445219 10.1177/0963689719859539 10.3389/fendo.2020.00050 10.3892/ijmm.2017.2897 10.1634/stemcells.2006-0286 10.1016/j.cellbi.2008.02.002 10.1177/1933719117732156 10.1016/j.ymthe.2017.04.019 10.1093/humupd/dmv037 10.1186/s13287-018-0772-x 10.1089/scd.2013.0371 10.1093/humrep/dem265 10.1016/j.biotechadv.2018.03.011 10.2174/1574888X14666190314123006 10.1186/scrt231 10.1186/s13048-020-00743-3 10.1089/scd.2013.0367 10.1186/s13287-018-1008-9 10.3390/cells8050467 10.1186/s13256-020-02426-5 10.5530/ami.2016.1.7 10.1073/pnas.1001198107 10.1007/s10815-018-1235-0 10.1530/JME-14-0220 10.1016/j.rbmo.2019.09.007 10.1016/j.theriogenology.2016.01.029 10.1093/humupd/dmp005 10.1016/j.pmrj.2015.02.003 10.1371/journal.pone.0007627 10.1159/000356329 10.1160/TH03-07-0440 10.1302/0301-620X.91B8.22546 10.1097/PHM.0b013e3181f1c1c7 10.31487/j.RGM.2020.01.02 10.1159/000491697 10.1007/s43032-020-00266-8 10.1007/s43032-020-00315-2
Reproductive Sciences (Thousand Oaks, Calif.); Ulin M, Cetin E et. al.

May 6th, 2021 - Premature ovarian insufficiency (POI) is a condition characterized by amenorrhea, hypergonadotropic hypogonadism, estrogen deficiency, and reduced follicle counts leading to infertility under the age of 40. POI occurs in approximately 1-3% of wome...

New insights into the diagnosis and management of bone health in premature ovarian insu...
https://doi.org/10.1080/13697137.2021.1917539
Climacteric : the Journal of the International Menopause ... Nguyen HH, Milat F et. al.

May 6th, 2021 - Premature ovarian insufficiency (POI), defined as a loss of ovarian function before the age of 40 years, is a life-changing diagnosis that has numerous long-term consequences. Musculoskeletal complications, including osteoporosis and fractures, ar...

The risk of menopausal symptoms in premenopausal breast cancer patients and current pha...
https://doi.org/10.1080/14740338.2021.1926980
Expert Opinion on Drug Safety; Lei YY, Yeo W

May 6th, 2021 - For young premenopausal breast cancer (BC) patients, adjuvant chemotherapy and other anti-cancer treatments can increase the risk of menopausal symptoms and may cause chemotherapy-related amenorrhea (CRA), infertility and premature ovarian insuffi...

Methods of Ovarian Tissue Cryopreservation: Is Vitrification Superior to Slow Freezing?...
https://doi.org/10.1007/s43032-021-00591-6
Reproductive Sciences (Thousand Oaks, Calif.); Kometas M, Christman GM et. al.

May 3rd, 2021 - After cancer treatment, female survivors often develop ovarian insufficiency or failure. Oocyte and embryo freezing are well-established fertility preservation options, but cannot be applied in pre-pubescent girls, in women with hormone-sensitive ...

Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR...
https://doi.org/10.1038/s41436-021-01177-y 10.1093/hmg/1.6.397 10.1126/science.aas9963 10.1126/science.7692601 10.1002/ajmg.1320380221 10.1002/mrdd.20005 10.1086/374321 10.1002/mds.21493 10.1038/nrneurol.2016.82 10.1002/1096-8628(200023)97:3<189::AID-AJMG1036>3.0.CO;2-J 10.1093/humrep/dem148 10.3389/fpsyt.2018.00564 10.1002/ajmg.b.32065 10.1097/GME.0000000000000658 10.1007/s10897-006-9049-0 10.1002/ajmg.a.35674 10.1007/s12687-016-0262-8 10.1002/ajmg.a.33122 10.1097/GIM.0b013e3181fa9fad 10.1097/AOG.0b013e318163be0b 10.1186/gm401 10.1016/j.jmoldx.2019.11.002 10.1093/humrep/deh635 10.1038/sj.ejhg.5201510 10.1097/gme.0b013e3181647762 10.1097/GIM.0b013e31821705e5 10.1002/ajmg.b.32277 10.1007/s10519-005-2792-4 10.1016/j.fertnstert.2004.11.059 10.1002/(SICI)1096-8628(19960809)64:2<428::AID-AJMG39>3.0.CO;2-F 10.1001/jama.1993.03510130075034 10.1016/0092-8674(91)90283-5 10.1097/00001648-199911000-00021 10.1038/sj.ijo.0802039 10.3389/fgene.2018.00173 10.1097/GIM.0b013e3181d0d40e 10.1007/s00439-005-1326-8 10.1093/humrep/dei432 10.1016/j.fertnstert.2008.01.098 10.1007/s10897-015-9862-4 10.1002/jgc4.1222
Genetics in Medicine : Official Journal of the American C... Allen EG, Charen K et. al.

Apr 30th, 2021 - Approximately 20-30% of women with an FMR1 premutation experience fragile X-associated primary ovarian insufficiency (FXPOI); however, current risk estimates based on repeat size only identify women with the midrange of repeats to be at the highes...

see more →

Guidelines  7 results

Committee Opinion No. 698 Summary: Hormone Therapy in Primary Ovarian Insufficiency.
https://doi.org/10.1097/AOG.0000000000002040
Obstetrics and Gynecology;

Apr 20th, 2017 - Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The s...

Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency.
https://doi.org/10.1097/AOG.0000000000002044
Obstetrics and Gynecology;

Apr 20th, 2017 - Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The s...

The British Menopause Society and Women's Health Concern recommendations on the managem...
https://doi.org/10.1177/2053369117699358
Post Reproductive Health; Hamoda H,

Apr 6th, 2017 - The British Menopause Society and Women's Health Concern recommendations on the management of women with premature ovarian insufficiency.|2017|Hamoda H, ,|epidemiology,etiology,adverse effects,methods,etiology,complications,drug therapy,etiology,p...

ESHRE Guideline: management of women with premature ovarian insufficiency.
https://doi.org/10.1093/humrep/dew027
Human Reproduction (Oxford, England); , Webber L et. al.

Mar 24th, 2016 - What is the optimal management of women with premature ovarian insufficiency (POI) based on the best available evidence in the literature? The guideline development group (GDG) formulated 99 recommendations answering 31 key questions on the diagno...

ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific...
https://doi.org/10.1038/gim.2013.61
Genetics in Medicine : Official Journal of the American C... Monaghan KG, Lyon E et. al.

Jun 14th, 2013 - Molecular genetic testing of the FMR1 gene is commonly performed in clinical laboratories. Mutations in the FMR1 gene are associated with fragile X syndrome, fragile X tremor ataxia syndrome, and premature ovarian insufficiency. This document prov...

see more →

Clinicaltrials.gov  1,623 results

Human Mesenchymal Stem Cell Therapy and Other Novel Treatment Approaches for Premature ...
https://doi.org/10.1007/s43032-021-00528-z 10.1016/S0140-6736(10)60355-8 10.1016/j.maturitas.2011.12.023 10.1210/er.2014-1020 10.1530/REP-13-0181 10.1016/j.rbmo.2015.06.015 10.1016/j.fertnstert.2013.11.009 10.1038/nrendo.2013.205 10.1258/ce.2009.009046 10.1186/s13287-019-1315-9 10.1186/s13287-017-0721-0 10.1371/journal.pone.0106538 10.1177/1933719117699705 10.1007/s11626-019-00337-4 10.1007/s11427-017-9272-2 10.1186/s13287-016-0458-1 10.1177/1933719117699705 10.1073/pnas.1312830110 10.4103/jhrs.JHRS_116_17 10.1016/j.fertnstert.2018.04.025 10.1080/09513590.2018.1445219 10.1177/0963689719859539 10.3389/fendo.2020.00050 10.3892/ijmm.2017.2897 10.1634/stemcells.2006-0286 10.1016/j.cellbi.2008.02.002 10.1177/1933719117732156 10.1016/j.ymthe.2017.04.019 10.1093/humupd/dmv037 10.1186/s13287-018-0772-x 10.1089/scd.2013.0371 10.1093/humrep/dem265 10.1016/j.biotechadv.2018.03.011 10.2174/1574888X14666190314123006 10.1186/scrt231 10.1186/s13048-020-00743-3 10.1089/scd.2013.0367 10.1186/s13287-018-1008-9 10.3390/cells8050467 10.1186/s13256-020-02426-5 10.5530/ami.2016.1.7 10.1073/pnas.1001198107 10.1007/s10815-018-1235-0 10.1530/JME-14-0220 10.1016/j.rbmo.2019.09.007 10.1016/j.theriogenology.2016.01.029 10.1093/humupd/dmp005 10.1016/j.pmrj.2015.02.003 10.1371/journal.pone.0007627 10.1159/000356329 10.1160/TH03-07-0440 10.1302/0301-620X.91B8.22546 10.1097/PHM.0b013e3181f1c1c7 10.31487/j.RGM.2020.01.02 10.1159/000491697 10.1007/s43032-020-00266-8 10.1007/s43032-020-00315-2
Reproductive Sciences (Thousand Oaks, Calif.); Ulin M, Cetin E et. al.

May 6th, 2021 - Premature ovarian insufficiency (POI) is a condition characterized by amenorrhea, hypergonadotropic hypogonadism, estrogen deficiency, and reduced follicle counts leading to infertility under the age of 40. POI occurs in approximately 1-3% of wome...

New insights into the diagnosis and management of bone health in premature ovarian insu...
https://doi.org/10.1080/13697137.2021.1917539
Climacteric : the Journal of the International Menopause ... Nguyen HH, Milat F et. al.

May 6th, 2021 - Premature ovarian insufficiency (POI), defined as a loss of ovarian function before the age of 40 years, is a life-changing diagnosis that has numerous long-term consequences. Musculoskeletal complications, including osteoporosis and fractures, ar...

The risk of menopausal symptoms in premenopausal breast cancer patients and current pha...
https://doi.org/10.1080/14740338.2021.1926980
Expert Opinion on Drug Safety; Lei YY, Yeo W

May 6th, 2021 - For young premenopausal breast cancer (BC) patients, adjuvant chemotherapy and other anti-cancer treatments can increase the risk of menopausal symptoms and may cause chemotherapy-related amenorrhea (CRA), infertility and premature ovarian insuffi...

Methods of Ovarian Tissue Cryopreservation: Is Vitrification Superior to Slow Freezing?...
https://doi.org/10.1007/s43032-021-00591-6
Reproductive Sciences (Thousand Oaks, Calif.); Kometas M, Christman GM et. al.

May 3rd, 2021 - After cancer treatment, female survivors often develop ovarian insufficiency or failure. Oocyte and embryo freezing are well-established fertility preservation options, but cannot be applied in pre-pubescent girls, in women with hormone-sensitive ...

Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR...
https://doi.org/10.1038/s41436-021-01177-y 10.1093/hmg/1.6.397 10.1126/science.aas9963 10.1126/science.7692601 10.1002/ajmg.1320380221 10.1002/mrdd.20005 10.1086/374321 10.1002/mds.21493 10.1038/nrneurol.2016.82 10.1002/1096-8628(200023)97:3<189::AID-AJMG1036>3.0.CO;2-J 10.1093/humrep/dem148 10.3389/fpsyt.2018.00564 10.1002/ajmg.b.32065 10.1097/GME.0000000000000658 10.1007/s10897-006-9049-0 10.1002/ajmg.a.35674 10.1007/s12687-016-0262-8 10.1002/ajmg.a.33122 10.1097/GIM.0b013e3181fa9fad 10.1097/AOG.0b013e318163be0b 10.1186/gm401 10.1016/j.jmoldx.2019.11.002 10.1093/humrep/deh635 10.1038/sj.ejhg.5201510 10.1097/gme.0b013e3181647762 10.1097/GIM.0b013e31821705e5 10.1002/ajmg.b.32277 10.1007/s10519-005-2792-4 10.1016/j.fertnstert.2004.11.059 10.1002/(SICI)1096-8628(19960809)64:2<428::AID-AJMG39>3.0.CO;2-F 10.1001/jama.1993.03510130075034 10.1016/0092-8674(91)90283-5 10.1097/00001648-199911000-00021 10.1038/sj.ijo.0802039 10.3389/fgene.2018.00173 10.1097/GIM.0b013e3181d0d40e 10.1007/s00439-005-1326-8 10.1093/humrep/dei432 10.1016/j.fertnstert.2008.01.098 10.1007/s10897-015-9862-4 10.1002/jgc4.1222
Genetics in Medicine : Official Journal of the American C... Allen EG, Charen K et. al.

Apr 30th, 2021 - Approximately 20-30% of women with an FMR1 premutation experience fragile X-associated primary ovarian insufficiency (FXPOI); however, current risk estimates based on repeat size only identify women with the midrange of repeats to be at the highes...

see more →

News  19 results

Primary Ovarian Insufficiency Linked to Osteoporosis
https://www.medscape.com/viewarticle/947390

Mar 14th, 2021 - NEW YORK (Reuters Health) - Primary ovarian insufficiency (POI) was tied to an increased risk of osteoporosis in a large Canadian cohort study. "There is accumulating evidence demonstrating that an earlier menopause, which represents an early loss...

UK Guidelines Quiz – Menopause: Diagnosis and Management
https://www.medscape.com/viewarticle/919637

Oct 17th, 2019 - In the reviewed guideline: ‘Menopause: diagnosis and management’ the National Institute for Health and Care Excellence (NICE) aims to improve the consistency of support and information provided to women in menopause. It includes guidance for the d...

No increase in primary ovarian insufficiency with HPV vaccine
https://www.mdedge.com/obgyn/article/172987/vaccines/no-increase-primary-ovarian-insufficiency-hpv-vaccine
Bianca Nogrady

Aug 21st, 2018 - The human papillomavirus vaccine does not appear to be associated with an increased risk of ovarian insufficiency, according to researchers. Choreograph/Thinkstock Allison L.

VIDEO: Dr. Matteo Lambertini answers questions on temporary ovarian suppression
https://www.mdedge.com/obgyn/article/153819/breast-cancer/video-dr-matteo-lambertini-answers-questions-temporary-ovarian
Susan London

Dec 7th, 2017 - SAN ANTONIO – A meta-analysis of five trials among 873 premenopausal women with early breast cancer finds that temporarily suppressing ovarian function with a gonadotropin-releasing hormone analog during chemotherapy helps preserve fertility, redu.

ESHRE writes first premature ovarian insufficiency guidelines
https://www.mdedge.com/internalmedicine/article/86417/gynecology/eshre-writes-first-premature-ovarian-insufficiency
Mitchel L. Zoler

Aug 12th, 2014 - MUNICH – A working group of the European Society of Human Reproduction and Embryology drafted the first international guidelines for managing premature ovarian insufficiency. Once formally released, by late this year or soon after, the guidelines.

see more →

Patient Education  9 results see all →